Options of precision medicine in pediatric oncology: literature review
Open Access
- 20 January 2022
- journal article
- review article
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 8 (4) , 71-80
Abstract
Возможности персонификации терапии в детской онкологии: обзор литературыKeywords
This publication has 49 references indexed in Scilit:
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in NeuroblastomaClinical Cancer Research, 2013
- Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium StudyClinical Cancer Research, 2013
- Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)PLOS ONE, 2013
- Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium ReportJournal of Clinical Oncology, 2013
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyThe Lancet Oncology, 2013
- The Pediatric Cancer Genome ProjectNature Genetics, 2012
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's SarcomaCancer Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivoOncogene, 2007
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing programPediatric Blood & Cancer, 2007